The Company is also studying P1101 in the single-arm phase 2B EXCEED-ET trial (ClinicalTrials.gov Identifier: NCT05482971) to evaluate the efficacy, safety, and tolerability of P1101 in adult patients ...

The NDA is supported by data from the open-label, single-center phase 1/2 90-CH-0149 trial and the open-label, single-arm phase 3 09-CH-0059 study.

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

Odds of complications significantly reduced with early anti-TNFα therapy, especially in those with perianal lesions ...

(HealthDay News)-— The A (H5N1) virus generally causes mild illness of short duration, mainly among US adults exposed to infected animals, according to a study published online Dec. 31 in the New ...

The FDA is expected to decide on treatments for Parkinson disease, PTSD and NF1-associated plexiform neurofibromas, in addition to 2 new vaccines.

(HealthDay News) — Racial and ethnic disparities are seen in the use of obesity management medications, according to a study published online Dec. 17 in the Journal of Racial and Ethnic Health ...

(HealthDay News) — Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more ...

Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age ...

An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined ...

The BLA acceptance was supported by data from the randomized, placebo-controlled phase 2b/3 CLEVER trial as well as interim data from the ongoing phase 3 SMART trial.